Today: 7 February 2026
Subscribe
Browse Category

Pharmaceutical Industry News 30 December 2025 - 9 January 2026

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

New York, Jan 9, 2026, 13:59 EST — Regular session Shares of Revolution Medicines climbed on Friday as investors weighed a report that Merck is in talks to buy the cancer-drug developer for up to $32 billion. Revolution was up about 4.3% at $112.00, after touching $125.79 earlier in the session. (Reuters) The chatter matters because Merck is hunting for oncology assets ahead of looming patent expirations on its blockbuster Keytruda, and dealmakers have been leaning harder into biotech after a busy year for healthcare M&A. A Revolution deal at that size would be one of the biggest pre-commercial biotech
9 January 2026
··
Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

New York, Jan 8, 2026, 18:23 EST — After-hours Shares of Eli Lilly fell 2.1% on Thursday, trading between $1,070.16 and $1,133.06, and were last at $1,085.19 in after-hours activity after the drugmaker reported late-stage data on a Zepbound-Taltz combination in psoriatic arthritis. Lilly said 31.7% of patients on the combo met a dual goal — at least 50% lower disease activity and at least 10% weight loss after 36 weeks — compared with 0.8% on Taltz alone. Senior vice president Mark Genovese said the results support an “integrated treatment approach” for the inflammatory joint disease, which affects up to
9 January 2026
··
Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens

New York, January 8, 2026, 14:40 EST — Regular session Arcus Biosciences (RCUS) shares slid 9.3% to $21.05 in afternoon trading on Thursday, after earlier touching $22.70. The stock hit a session low of $21.02. Morgan Stanley cut its rating on Arcus to “equal weight” from “overweight” and trimmed its price target to $20 from $23, Investing.com reported, calling the risk-reward more balanced after a strong 2025 run. The Nasdaq Biotechnology Index was down about 2.8%. Investing.com Arcus laid out its 2026 playbook late Wednesday, keeping casdatifan — which it has billed as a potential best-in-class HIF-2a inhibitor, a protein
8 January 2026
··
Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

New York, Jan 7, 2026, 17:32 EST — After-hours Shares of Ventyx Biosciences (VTYX.O) jumped on Wednesday after Eli Lilly (LLY.N) agreed to buy the San Diego-based biotech in a $14-per-share all-cash deal. Ventyx closed up about 37% at $13.81 and was last at $13.73 in after-hours trading, still shy of the offer price. Yahoo Finance For Lilly, the deal is a small bolt-on at a moment when the drugmaker is flush from sales of its diabetes and weight-loss medicines. Cantor Fitzgerald analyst Carter Gould called the price tag “borderline immaterial” for Lilly and said the company is taking shots
7 January 2026
···
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

New York, January 6, 2026, 15:27 (ET) — Regular session Nasdaq-listed Travere Therapeutics shares fell 5.3% to $36.09 in afternoon trading on Tuesday as investors looked toward next week’s U.S. FDA decision deadline on expanding its kidney drug Filspari (sparsentan) into focal segmental glomerulosclerosis. The FDA’s Prescription Drug User Fee Act, or PDUFA, target action date is Jan. 13, and the stock has ranged from $34.88 to $39.16 in the session. SEC The case matters for Travere because FSGS is a rare disease that scars the kidney’s filtering units and can progress to kidney failure. An added label would broaden
6 January 2026
··
JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

JNJ stock slips as talc lawsuits return to the spotlight ahead of earnings

New York, January 5, 2026, 14:35 ET — Regular session Johnson & Johnson (JNJ) stock fell about 2.2% on Monday as investors trimmed defensive healthcare names. Shares were down $4.49 at $202.86 in afternoon trading after touching a session low of $200.94, with about 4.8 million shares traded. The timing matters because early-year positioning has shifted quickly toward cyclicals, leaving traditionally steady names with less of a bid. When money flows out of defensives, big healthcare stocks can slide even without a single headline. Investors are also recalibrating around legal and earnings catalysts that can reprice a stock in a
5 January 2026
···
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

NEW YORK, January 1, 2026, 16:58 ET — Market closed Axsome Therapeutics shares jumped about 23% in the most recent session on Wednesday after the company said the U.S. Food and Drug Administration accepted its supplemental application for AXS-05 to treat agitation in Alzheimer’s disease and granted the filing priority review. The stock last traded at $182.64, after swinging between $148.79 and $184.40 on volume of about 3.1 million shares. Businessinsider Why it matters now: priority review shortens the FDA’s review target to six months, versus 10 months under the standard process, pulling a key binary catalyst into the first
1 January 2026
···
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

NEW YORK, January 1, 2026, 10:45 ET — Market closed. Corcept Therapeutics Inc (CORT) shares last ended Wednesday down 50.4% at $34.80 after the company said U.S. regulators were not ready to approve its drug relacorilant for a form of high blood pressure linked to hypercortisolism. U.S. stock markets are shut on Thursday for New Year’s Day. HCPLive The selloff matters because relacorilant was the company’s key near-term bet to broaden its commercial base beyond its current product, and the FDA’s response forces investors to reassess both timing and risk. It also sharpens focus on Corcept’s oncology program. In the
1 January 2026
··
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

NEW YORK, December 31, 2025, 18:31 ET — After-hours Corcept Therapeutics Inc shares sank about 50% in after-hours trading on Wednesday after the U.S. Food and Drug Administration declined to approve its oral drug relacorilant for a Cushing’s-related hypertension use. The stock was last at $34.80, down $35.39 from the prior close. Reuters The decision hits at a key moment for Corcept, which investors have looked to relacorilant to expand the company’s business beyond its marketed drug Korlym. A regulatory setback for relacorilant raises the risk that Corcept’s next growth driver takes longer—and costs more—to reach the market. Reuters Corcept
1 January 2026
··
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

NEW YORK, December 31, 2025, 11:19 ET — Regular session Abivax Société Anonyme’s U.S.-listed American depositary shares (ABVX) fell about 3.8% to $133.04, down roughly $5.30 from Tuesday’s close, in late morning trade on Wednesday. The shares opened at $138 and swung between $132.13 and $140.25, with about 348,000 shares traded. The pullback keeps the spotlight on ABVX after takeover chatter earlier this month. Reuters reported on Dec. 10 that Abivax jumped on market rumours that Eli Lilly could make an offer, and Stifel analyst Damien Choplain said the “share price movement is driven by speculation around a possible takeover.”
31 December 2025
··
Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY

Bristol-Myers Squibb stock edges higher as Wall Street drifts into year-end — what’s next for BMY

NEW YORK, December 30, 2025, 23:30 ET — Market closed Bristol-Myers Squibb Co. shares closed up 0.18% at $54.21 on Tuesday, after trading between $53.92 and $54.35. The stock has ranged from $42.52 to $63.33 over the past 52 weeks. Bristol Myers Squibb Investors The modest gain came as Wall Street drifted lower in holiday-thinned trade. “The growth rates are going to converge between technology and everything else next year,” said Mark Hackett, chief market strategist at Nationwide, as investors repositioned after a tech-led run; the S&P 500 slipped 0.14% and the Nasdaq fell 0.23%. Reuters Why it matters now:
31 December 2025
··
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

NEW YORK, December 30, 2025, 14:54 ET — Regular session Shares of Praxis Precision Medicines Inc (NASDAQ: PRAX) slipped about 3% on Tuesday, giving back part of a sharp rally sparked by an FDA regulatory boost for its lead essential tremor program. The stock was down 3% at $295.50 as of 2:39 p.m. ET, after opening at $304.00 and trading between $286.58 and $304.70. The company said on Monday the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for ulixacaltamide to treat essential tremor, and said the decision was based on positive topline results from the Essential3 program, two
30 December 2025
··
1 2 3 4 5 6 … 12

Stock Market Today

Lucid stock jumps 14% as Dow tops 50,000 — what LCID investors watch next week

Lucid stock jumps 14% as Dow tops 50,000 — what LCID investors watch next week

7 February 2026
Lucid Group shares jumped 14% to $10.86 at Friday’s close, recovering from an 8% drop the previous day. The move followed a broad Wall Street rally that lifted high-volatility stocks. Lucid reported fourth-quarter deliveries of 5,345 vehicles and full-year deliveries of 15,841. Investors await Lucid’s Feb. 24 results for updates on cash and demand.
Go toTop